Skip to main content

Eli Lilly's Zepbound and Mounjaro now available in U.S. after shortages, FDA says

Demand for weight loss and diabetes drugs has trounced supply for months, pushing Eli Lilly and its rival Novo Nordisk to invest billions to ramp up manufacturing.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.